Literature DB >> 14729635

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Thomas W Davis1, Janet M O'Neal, Mark D Pagel, Ben S Zweifel, Pramod P Mehta, Deborah M Heuvelman, Jaime L Masferrer.   

Abstract

Previous work has demonstrated that selective cyclooxygenase-2 (COX-2) inhibitors can act synergistically with radiotherapy to improve tumor debulking and control in preclinical models. The underlying mechanism of this remarkable activity has not yet been determined. Here, we report that radiation can elevate intratumoral levels of COX-2 protein and its products, particularly prostaglandin E(2) (PGE(2)). Furthermore, inhibition of COX-2 activity or neutralization of PGE(2) activity enhances radiotherapy even in tumors where COX-2 expression is restricted to the tumor neovasculature. Direct assessment of vascular function by direct contrast enhancement-magnetic resonance imaging showed that the combination of radiation and celecoxib lead to enhanced vascular permeability. These observations suggest that an important mechanism of celecoxib-induced radiosensitization involves inhibition of COX-2-derived PGE(2), thus removing a survival factor for the tumor and its vasculature.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729635     DOI: 10.1158/0008-5472.can-03-1168

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

Authors:  Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

4.  Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.

Authors:  Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.

Authors:  Imtiyaz A Bhat; Roohi Rasool; Iqbal Qasim; Khalid Z Masoodi; Shabeer A Paul; Bashir A Bhat; Farooq A Ganaie; Sheikh A Aziz; Zafar A Shah
Journal:  Tumour Biol       Date:  2014-08-12

6.  Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.

Authors:  Julio Cárdenas-Rodríguez; Yuguo Li; Jean-Philippe Galons; Heather Cornnell; Robert J Gillies; Mark D Pagel; Amanda F Baker
Journal:  Magn Reson Imaging       Date:  2012-05-01       Impact factor: 2.546

7.  Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation.

Authors:  Teresa G Tessner; Filipe Muhale; Terrence E Riehl; Shrikant Anant; William F Stenson
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

8.  Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

Authors:  Shibo Fu; Michael Rivera; Eric C Ko; Andrew G Sikora; Chien-Ting Chen; Ha Linh Vu; David Cannan; Samuel Eisenstein; Barry S Rosenstein; Julio Aguirre-Ghiso; Shu-Hsia Chen; Johnny Kao
Journal:  J Cell Sci Ther       Date:  2011-10-13

Review 9.  The role of COX-2 in intestinal inflammation and colorectal cancer.

Authors:  D Wang; R N Dubois
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

10.  Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.

Authors:  Martin Scheer; Uta Drebber; Kai Breuhahn; Christoph Möckel; Tobias Reuther; Michael Kern; Joachim E Zöller
Journal:  Oral Maxillofac Surg       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.